Does gender influence the outcomes of total ankle arthroplasty in patients with ankle osteoarthritis?

Autor: Gun-Woo Lee; Keun-Bae Lee
Sprache: Englisch
Veröffentlicht: 2020
Quelle: Directory of Open Access Journals: DOAJ Articles
Online Zugang: http://link.springer.com/article/10.1186/s13018-020-01731-5
https://doaj.org/toc/1749-799X
doi:10.1186/s13018-020-01731-5
1749-799X
https://doaj.org/article/3f258d16adc047b0a8f1171944c6c79c
https://doi.org/10.1186/s13018-020-01731-5
https://doaj.org/article/3f258d16adc047b0a8f1171944c6c79c
Erfassungsnummer: ftdoajarticles:oai:doaj.org/article:3f258d16adc047b0a8f1171944c6c79c

Zusammenfassung

Abstract Background Total ankle arthroplasty has progressed as a treatment option for patients with ankle osteoarthritis. However, no studies have been conducted to evaluate the effect of gender on the outcome. The purpose of the present study was to evaluate outcomes, survivorship, and complications rates of total ankle arthroplasty, according to gender differences. Methods This study included 187 patients (195 ankles) that underwent mobile-bearing HINTEGRA prosthesis at a mean follow-up of 7.5 years (range, 4 to 14). The two groups consisted of a men’s group (106 patients, 109 ankles) and a women’s group (81 patients, 86 ankles). Average age was 64.4 years (range, 45 to 83). Results Clinical scores on the Ankle Osteoarthritis Scale for pain and disability, and American Orthopaedic Foot and Ankle Society ankle-hindfoot score improved and the difference was not statistically significant between the two groups at the final follow-up. There were no significant differences in complication rates and implant survivorship between the two groups. The overall survival rate was 96.4% in men and 93.4% in women at a mean follow-up of 7.5 years (p = 0.621). Conclusions Clinical outcomes, complication rates, and survivorship of total ankle arthroplasty were comparable between men and women. These results suggest that gender did not seem to affect outcomes of total ankle arthroplasty in patients with ankle osteoarthritis. Level of evidence Therapeutic level III